AIC
SABS icon

AWM Investment Company’s SAB Biotherapeutics SABS Stock Holding History

AWM Investment Company’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53M Buy
400,000
+200,000
+100% +$797K 0.17% 81
2025
Q4 		$748K Hold
200,000
– – 0.07% 98
2025
Q3 		$402K Buy
+200,000
New +$452K 0.04% 102

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AWM Investment Company's SABS Position: Q1 2026 in Review

AWM Investment Company increased its SAB Biotherapeutics (SABS) stake by 100% in Q1 2026, buying an estimated $797K and bringing the position to 400,000 shares worth $1.53M. The position accounts for 0.17% of the portfolio, ranked #81.

AWM Investment Company first reported a position in SABS in Q3 2025 and has held it in 3 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • AWM Investment Company held 400,000 shares of SAB Biotherapeutics worth $1.53M as of Q1 2026.
  • AWM Investment Company bought 200,000 SAB Biotherapeutics shares in Q1 2026, an estimated $797K.
  • SAB Biotherapeutics made up 0.17% of AWM Investment Company's portfolio in Q1 2026, its #81 holding.
  • AWM Investment Company first reported a position in SAB Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on AWM Investment Company's 13F filing for Q1 2026, filed 15 May 2026.